An interventional study of Hesperidin and Placebo in Multiple Sclerosis, sponsored by Swansea University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Swansea University · Not applicable, Interventional, and Treatment
Among 252 studies in Multiple Sclerosis with a site in United Kingdom — 28 open to participants now, 46 under way, 11 of them phase 3. Multiple Sclerosis · United Kingdom.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, this one is the 126th largest by planned enrollment of the 195 interventional ones that give a count, is one of 5 that started in 2026, is one of 43 with no phase, reaches primary completion later than 19 of the 45 other live ones, and was the 247th registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 60 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →28 of the 252 studies in Multiple Sclerosis with a site in United Kingdom are open now, in 12 countries. Each count lists the studies.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →252 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2026.
Median enrollment 136 across the 195 interventional studies, 200 across the 57 observational. Of the 187 that completed or were terminated, 94 (50%) have results posted.
154 of 252 have an industry lead sponsor. The 10 most frequent:
Swansea University is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Swansea University has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Multiple Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT05781113Celestra Health SystemsA Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition | 2026-11-01 |
| NCT06274671University of ExeterGlymphatic MRI in Clinically Isolated Syndrome | 2026-12-31 |
| NCT07452562Swansea UniversityHesperidin RCT in MS | 2027-01-18 |
| NCT07111637Queen Mary University of LondonArtificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis | 2027-04-14 |
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, from their registry updates:
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.
Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Multiple Sclerosis (MS) is a chronic autoimmune condition characterized by neuro-inflammation, oxidative stress, and demyelination, often resulting in debilitating fatigue and cognitive dysfunction. While disease-modifying therapies exist, there is a significant need for accessible, low-risk adjunct interventions to manage these daily symptoms.
Hesperidin is a flavanone found primarily in citrus fruits (e.g., oranges, lemons). Preclinical research using Experimental Autoimmune Encephalomyelitis (EAE)-the standard animal model for MS-has demonstrated that hesperidin supplementation can reduce disease severity and incidence, likely due to its potent anti-inflammatory and antioxidant properties. However, there is a paucity of randomized controlled trials translating these findings to human MS populations.
Study Design \& Methodology. This study is a remote, randomised, double-blind, placebo-controlled, parallel-group trial in adults with Multiple Sclerosis. Participants will be randomized to receive either 500mg/day of Hesperidin or a matching placebo for a duration of 12 weeks.
Statistical Analysis Plan. Data will be analysed using linear mixed-effects models. For the primary outcome (MFIS total score) and each secondary outcome, change from baseline to week 12 will be compared between intervention and placebo using fixed effects for group, time (baseline, week 12), and the group × time interaction, with a participant-level random intercept. The treatment effect will be estimated from the group × time interaction. Exploratory analyses will test whether baseline habitual diet modifies the intervention effect by adding a diet × group × time interaction term, with habitual diet operationalised using FFQ-derived polyphenol intake (energy-adjusted) and the Dietary Inflammatory Index (DII). In addition, exploratory symptom network analyses will examine whether the pattern of associations among symptoms differs between groups and changes from baseline to week 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receiving Hesperidin capsules for 12 weeks.
Dietary Supplement: Hesperidin
Participants receiving matching placebo capsules for 12 weeks.
Dietary Supplement: Placebo
500 mg/day Hesperidin capsules for 12 weeks
Matching maltodextrin capsules for 12 weeks.
Fatigue
Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS; Fisk et al., 1994), with the MFIS total score as the primary endpoint. MFIS subscale scores (physical, cognitive, psychosocial) and the Fatigue Severity Scale (FSS; Krupp et al., 1989) will be analysed as secondary outcomes to determine effects across different components of fatigue.
Time frame: Baseline and Week 12
Mood and Stress
Mood and stress symptoms will be assessed using the Depression Anxiety Stress Scales (DASS). Secondary outcomes will include the Depression, Anxiety, and Stress subscale scores.
Time frame: Baseline and Week 12
Cognitive Function Battery
Global cognitive performance will be summarised using a composite score calculated as the mean of standardized (z) scores from a prespecified cognitive battery including: Continuous Performance Task (attention), Auditory Verbal Learning Task (verbal memory), Digit Symbol Substitution Task (speed of information processing), Stroop Task (selective attention/inhibitory control), and Trail Making Task (processing speed/set-shifting). Scores will be coded so that higher values indicate better performance (completion time measures will be reverse-scored prior to standardisation).Individual task outcomes will also be analysed separately to explore domain-specific effects (attention, memory, speed). Fatigue/mood ratings are taken before and after the test to assess cognitive fatigue relating to the tests.
Time frame: Baseline and Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hesperidin
Swansea University